Use Your Smartphone
to Keep an Eye on your Skin!  

Miiskin was established to meet the frustrations of facing the ongoing concern of checking his partner’s moles by orders from the doctor. Five years later, Miiskin was already an award winning and world leading skin tracking and monitoring platform.

Skin cancer accounts for more diagnoses each year than all other cancers. Nevertheless, the good news is that early detection can be the difference between a simple removal or malignant cancer that spreads to other parts of the body. Consequently, Miiskin has developed an app that can monitor, track, map and compare skin and moles images over time in a repeated process between doctor visits. By capturing photos, the Miiskin app assists the users to identify and document changes in their skin.

The app has reached high recognition and has already been downloaded +500,000 times and partnered with Kræftens Bekæmpelse (The Danish Cancer Society). It is the only app to be dermatologically endorsed and the only skin cancer prevention app approved by NHS (the largest public healthcare system in the world). Moreover, it has been promoted as App Of The Day twice by Apple.

Demand for more precise measurement

Absolute mole size and growth is, however, very difficult to measure as using a physical ruler comes with a high degree of uncertainty. Moreover, the distance between the camera lens and the mole can vary a lot from picture to picture. Lastly, growth and changes in colour are difficult to measure precisely with the bare eye. Therefore, both users and doctors are crying out for a more precise measurements and more accurate track and document changes.

Innobooster Funding to Accelerate Development

Meeting this need, Miiskin has set the aim to develop an Automated Mole Sizing system that combines the latest machine learning modelling with a real time augmented reality user interface. In this connection, Nordic Innovators helped Miiskin to hand in a successful funding application for the Danish Innobooster programme.

“We ultimately aim at ending skin cancer mortality by 2040 by being the most trusted, secure and clinically reviewed tool for monitoring skin changes that can lead to early detection of melanoma and be the difference between life and death. An essential step towards this is to automate and improve the user’s interaction and ability to accurate measure mole size and evolution in size and colours over time,” says Jon Friis, founder of Miiskin.